tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka and Telangana

Story Highlights
  • MedPlus operates in the healthcare industry with a focus on pharmaceutical products.
  • Optival Health Solutions received drug license suspensions, impacting revenue by Rs 2.88 lacs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MedPlus Subsidiary Faces Drug License Suspensions in Karnataka and Telangana

TipRanks Cyber Monday Sale

MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has issued an update.

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at three of its stores located in Karnataka and Telangana. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 2.88 lacs. This development may impact the company’s short-term financial operations, but the overall implications for its market positioning remain to be seen.

More about MedPlus Health Services Ltd.

MedPlus Health Services Ltd. operates in the healthcare industry, focusing on providing pharmaceutical products and services. It is a prominent player in the Indian market, with a network of retail pharmacies offering a wide range of health and wellness products.

Average Trading Volume: 21,258

Technical Sentiment Signal: Hold

Current Market Cap: 94.82B INR

For detailed information about MEDPLUS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1